[Skip to Content]
[Skip to Content Landing]
August 1972

Topical Lomustine in the Treatment of Psoriasis

Author Affiliations

Bethesda, Md

From the Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md.

Arch Dermatol. 1972;106(2):172-176. doi:10.1001/archderm.1972.01620110008002

Nine of 12 patients treated in a double-blind manner with topical 1.0% lomustine had complete resolution of psoriatic plaques in four to six weeks. Local toxicity included cutaneous irritation with epidermal separation, hyperpigmentation, telangiectasia, and cutaneous pain and pruritus. Two patients developed temporary bone marrow suppression. At present, four of the 12 patients have received 18-month remissions.